Clinicopathological and histological analysis of secondary malignant giant cell tumors of bone without radiotherapy

Nakata,Eiji; Kawai,Hotaka; Fujiwara,Tomohiro; Kunisada,Toshiyuki; Inoue,Hirofumi; Futagawa,Mashu; Katayama,Haruyoshi; Itano,Takuto; Ozaki,Toshifumi

doi:10.3892/ol.2022.13439

Clinicopathological and histological analysis of secondary malignant giant cell tumors of bone without radiotherapy

Authors:
- Eiji Nakata
- Hotaka Kawai
- Tomohiro Fujiwara
- Toshiyuki Kunisada
- Hirofumi Inoue
- Mashu Futagawa
- Haruyoshi Katayama
- Takuto Itano
- Toshifumi Ozaki
View Affiliations

Affiliations: Department of Orthopedic Surgery, Okayama University Hospital, Okayama 700‑8558, Japan, Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700‑8558, Japan, Department of Pathology, Okayama University Hospital, Okayama 700‑8558, Japan, Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700‑8558, Japan
Published online on: July 19, 2022 https://doi.org/10.3892/ol.2022.13439
Article Number: 319
Copyright: © Nakata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Giant cell tumor of bone (GCTB) is an intermediate bone tumor that rarely undergoes malignant transformation. Secondary malignant GCTB (SMGCTB) is defined as a lesion in which high‑grade sarcoma occurs at the site of previously treated GCTB. The present study retrospectively reviewed the medical records of patients with GCTB treated at Okayama University Hospital between April 1986 and April 2020. The clinicopathological and histological features of patients with SMGCTB without prior radiotherapy were investigated. A total of three patients (4%) with SMGCTB were detected, and the tumor sites were the distal ulna, distal femur and sacrum. Two of the patients had been treated with curettage and bone graft, and one had been treated with denosumab. In all cases, the lesions were made up of two components, the conventional GCTB component and the malignant component. The Ki67 labeling index was higher in the malignant components of SMGCTB and metastatic lesions compared with that in primary and recurrent conventional GCTB, or the conventional GCTB component of SMGCTB. Moreover, p53 expression was higher in these same components in patients who underwent curettage and bone grafting; however, there was no difference in the patient that received denosumab treatment. In this patient, clinical cancer genomic profiling revealed loss of CDKN2A, CDKN2B and MTAP expression. All three patients developed distant metastasis. The patients with SMGCTB in the ulna and femur died 13 and 54 months after detection of malignant transformation, respectively. The patient with SMGCTB in the sacrum received carbon‑ion radiotherapy to the sacrum and pazopanib; the treatment was effective and the patient was alive at the last follow‑up 3 years later. In conclusion, p53 may be associated with malignant transformation in GCTB. Future studies should investigate the association of between denosumab treatment and malignant transformation, as well as molecular targeted therapy to improve the clinical outcomes of SMGCTB.

View Figures

View References

1	Basu Mallick A and Chawla SP: Giant cell tumor of bone: An update. Curr Oncol Rep. 23:512021. View Article : Google Scholar : PubMed/NCBI
2	Errani C, Tsukamoto S, Ciani G and Donati DM: Present day controversies and consensus in curettage for giant cell tumor of bone. J Clin Orthop Trauma. 10:1015–1020. 2019. View Article : Google Scholar : PubMed/NCBI
3	Tsukamoto S, Mavrogenis AF, Kido A and Errani C: Current concepts in the treatment of giant cell tumors of bone. Cancers (Basel). 13:36472021. View Article : Google Scholar : PubMed/NCBI
4	Gupta A, Durocher-Allen L, Popovic S, Tozer R, Yao X and Ghert M: The role of denosumab for surgical outcomes in patients with giant cell tumour of bone: A systematic review. Curr Oncol. 28:1302–1313. 2021. View Article : Google Scholar : PubMed/NCBI
5	Li H, Gao J, Gao Y, Lin N, Zheng M and Ye Z: Denosumab in giant cell tumor of bone: Current status and pitfalls. Front Oncol. 10:5806052020. View Article : Google Scholar : PubMed/NCBI
6	Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, et al: Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study. Lancet Oncol. 11:275–280. 2010. View Article : Google Scholar : PubMed/NCBI
7	Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, et al: Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study. Lancet Oncol. 20:1719–1729. 2019. View Article : Google Scholar : PubMed/NCBI
8	Palmerini E, Picci P, Reichardt P and Downey G: Malignancy in giant cell tumor of bone: A review of the literature. Technol Cancer Res Treat. 18:15330338198400002019. View Article : Google Scholar : PubMed/NCBI
9	Murphy WR and Ackerman LV: Benign and malignant giant-cell tumors of bone; a clinical-pathological evaluation of thirty-one cases. Cancer. 9:317–339. 1956. View Article : Google Scholar : PubMed/NCBI
10	Mnaymneh WA, Dudley HR and Mnaymneh LG: Giant-cell tumor of bone: An analysis and follow-up study of the forty-one cases observed at the Massachusetts general hospital between 1925 and 1960. J Bone Joint Surg Am. 46:63–75. 1964. View Article : Google Scholar : PubMed/NCBI
11	Dahlin DC, Cupps RE and Johnson EW: Giant-cell tumor: A study of 195 cases. Cancer. 25:1061–1070. 1970. View Article : Google Scholar : PubMed/NCBI
12	Sundaram M, Martin AS and Tayob AA: Case report 182: Osteosarcoma arising in giant cell tumor of tibia. Skeletal Radiol. 7:282–285. 1982. View Article : Google Scholar : PubMed/NCBI
13	Rock MG, Sim FH, Unni KK, Witrak GA, Frassica FJ, Schray MF, Beabout JW and Dahlin DC: Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg Am. 68:1073–1079. 1986. View Article : Google Scholar : PubMed/NCBI
14	Gitelis S, Wang JW, Quast M, Schajowicz F and Templeton A: Recurrence of a giant-cell tumor with malignant transformation to a fibrosarcoma twenty-five years after primary treatment. A case report. J Bone Joint Surg Am. 71:757–761. 1989. View Article : Google Scholar : PubMed/NCBI
15	Hefti FL, Gächter A, Remagen W and Nidecker A: Recurrent giant-cell tumor with metaplasia and malignant change, not associated with radiotherapy. A case report. J Bone Joint Surg Am. 74:930–934. 1992. View Article : Google Scholar : PubMed/NCBI
16	Anract P, De Pinieux G, Cottias P, Pouillart P, Forest M and Tomeno B: Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: A review of 29 cases. Int Orthop. 22:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
17	Mori Y, Tsuchiya H, Karita M, Nonomura A, Nojima T and Tomita K: Malignant transformation of a giant cell tumor 25 years after initial treatment. Clin Orthop Relat Res. 381:185–191. 2000. View Article : Google Scholar : PubMed/NCBI
18	Oda Y, Sakamoto A, Saito T, Matsuda S, Tanaka K, Iwamoto Y and Tsuneyoshi M: Secondary malignant giant-cell tumour of bone: Molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology. 39:629–637. 2001. View Article : Google Scholar : PubMed/NCBI
19	Marui T, Yamamoto T, Yoshihara H, Kurosaka M, Mizuno K and Akamatsu T: De novo malignant transformation of giant cell tumor of bone. Skeletal Radiol. 30:104–108. 2001. View Article : Google Scholar : PubMed/NCBI
20	Bertoni F, Bacchini P and Staals EL: Malignancy in giant cell tumor of bone. Cancer. 97:2520–2529. 2003. View Article : Google Scholar : PubMed/NCBI
21	Hashimoto K, Hatori M, Hosaka M, Watanabe M, Hasegawa T and Kokubun S: Osteosarcoma arising from giant cell tumor of bone ten years after primary surgery: A case report and review of the literature. Tohoku J Exp Med. 208:157–162. 2006. View Article : Google Scholar : PubMed/NCBI
22	Machinami R, Nishida K, Ishida T, Matsumoto S, Kuroda K, Kobayashi M, Takeuchi K and Ishikawa Y: Carcinosarcomatous malignancy, osteosarcoma and squamous cell carcinoma, in giant cell tumor of the right distal femur. Pathol Res Pract. 204:583–588. 2008. View Article : Google Scholar : PubMed/NCBI
23	Miller IJ, Blank A, Yin SM, McNickle A, Gray R and Gitelis S: A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases. Diagn Pathol. 5:622010. View Article : Google Scholar : PubMed/NCBI
24	Picci P, Sieberova G, Alberghini M, Balladelli A, Vanel D, Hogendoorn PC and Mercuri M: Late sarcoma development after curettage and bone grafting of benign bone tumors. Eur J Radiol. 77:19–25. 2011. View Article : Google Scholar : PubMed/NCBI
25	Kadowaki M, Yamamoto S and Uchio Y: Late malignant transformation of giant cell tumor of bone 41 years after primary surgery. Orthopedics. 35:e1566–e1570. 2012. View Article : Google Scholar : PubMed/NCBI
26	Muramatsu K, Ihara K, Miyoshi T, Kawakami Y, Nakashima D and Taguchi T: Late development of malignant fibrous histiocytoma at the site of a giant cell tumour 38 years after initial surgery. Acta Orthop Belg. 78:279–284. 2012.PubMed/NCBI
27	Li J, Zhu Y and Wei Y: Fibrosarcoma development 15 years after curettage and bone grafting of giant cell tumor of bone. Orthopedics. 37:e512–e516. 2014. View Article : Google Scholar : PubMed/NCBI
28	Yin H, Cheng M, Li B, Li B, Wang P, Meng T, Wang J, Zhou W, Yan W and Xiao J: Treatment and outcome of malignant giant cell tumor in the spine. J Neurooncol. 124:275–281. 2015. View Article : Google Scholar : PubMed/NCBI
29	Takesako H, Osaka E, Yoshida Y, Sugitani M and Tokuhashi Y: Secondary malignant giant cell tumor of bone due to malignant transformation 40 years after surgery without radiation therapy, presenting as fever of unknown origin: A case report. J Med Case Rep. 10:472016. View Article : Google Scholar : PubMed/NCBI
30	Liu W, Chan CM, Gong L, Bui MM, Han G, Letson GD, Yang Y and Niu X: Malignancy in giant cell tumor of bone in the extremities. J Bone Oncol. 26:1003342020. View Article : Google Scholar : PubMed/NCBI
31	Tsukamoto S, Righi A, Mavrogenis AF, Akahane M, Honoki K, Tanaka Y, Donati DM and Errani C: Late local recurrence of bone giant cell tumors associated with an increased risk for malignant transformation. Cancers (Basel). 13:36442021. View Article : Google Scholar : PubMed/NCBI
32	Alaqaili SI, Abduljabbar AM, Altaho AJ, Khan AA and Alherabi JA: Malignant sarcomatous transformation of benign giant cell tumor of bone after treatment with denosumab therapy: A literature review of reported cases. Cureus. 10:e37922018.PubMed/NCBI
33	Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, et al: Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 22:2860–2868. 2015. View Article : Google Scholar : PubMed/NCBI
34	Broehm CJ, Garbrecht EL, Wood J and Bocklage T: Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case Rep Med. 2015:7671982015. View Article : Google Scholar : PubMed/NCBI
35	Aponte-Tinao LA, Piuzzi NS, Roitman P and Farfalli GL: A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res. 473:3050–3055. 2015. View Article : Google Scholar : PubMed/NCBI
36	Park A, Cipriano CA, Hill K, Kyriakos M and McDonald DJ: Malignant transformation of a giant cell tumor of bone treated with denosumab: A case report. JBJS Case Connect. 6:e782016. View Article : Google Scholar : PubMed/NCBI
37	Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM and Errani C: Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol. 47:1090–1096. 2017. View Article : Google Scholar : PubMed/NCBI
38	Hasenfratz M, Mellert K, Marienfeld R, von Baer A, Schultheiss M, Roitman PD, Aponte-Tinao LA, Lehner B, Möller P, Mechtersheimer G and Barth TFE: Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation. Sci Rep. 11:57092021. View Article : Google Scholar : PubMed/NCBI
39	Yung D, Asano N, Hirozane T, Yamaguchi S, Mori T, Susa M, Okita H, Morioka H, Horiuchi K and Nakayama R: Malignant transformation of metastatic giant cell tumor of bone in a patient undergoing denosumab treatment: A case report. J Orthop Sci. S0949-2658(21)00222-0. 2021.(Epub ahead of print). View Article : Google Scholar
40	Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D and Picci P: Malignancy in giant cell tumor of bone: Analysis of an open-label phase 2 study of denosumab. BMC Cancer. 21:892021. View Article : Google Scholar : PubMed/NCBI
41	Gong L, Liu W, Sun X, Sajdik C, Tian X, Niu X and Huang X: Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch. 460:327–334. 2012. View Article : Google Scholar : PubMed/NCBI
42	Okubo T, Saito T, Mitomi H, Takagi T, Torigoe T, Suehara Y, Kaneko K and Yao T: p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1. Virchows Archiv. 463:67–77. 2013. View Article : Google Scholar : PubMed/NCBI
43	Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA and Kurzrock R: Next-Generation sequencing in the clinical setting clarifies patient characteristics and potential actionability. Cancer Res. 77:6313–6320. 2017. View Article : Google Scholar : PubMed/NCBI
44	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
45	Ishihara S, Yamamoto H, Iwasaki T, Toda Y, Yamamoto T, Yoshimoto M, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, et al: Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: A possible association with TP53 mutation and loss of H3K27 trimethylation. Mod Pathol. 35:640–648. 2022. View Article : Google Scholar : PubMed/NCBI
46	Movahedinia S, Shooshtarizadeh T and Mostafavi H: Secondary malignant transformation of giant cell tumor of bone: Is it a fate? Iran J Pathol. 14:165–174. 2019. View Article : Google Scholar : PubMed/NCBI
47	Miranda Alcalde B, Villa Alcázar M, Martínez Romera I and López Ibor B: The importance of Li-Fraumeni syndrome, a hereditary cancer predisposition disorder. Arch Argent Pediatr. 119:e11–e17. 2021.Mantovani F, Collavin L and Del Sal G: Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26, 199–212, 2019. PubMed/NCBI
48	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
49	González-Gil C, Ribera J, Ribera JM and Genescà E: The Yin and Yang-like clinical implications of the CDKN2A/ARF/CDKN2B gene cluster in acute lymphoblastic leukemia. Genes (Basel). 12:792021. View Article : Google Scholar : PubMed/NCBI
50	Gong L, Bui MM, Zhang W, Sun X, Zhang M and Yi D: H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors. Histol Histopathol. 36:61–68. 2021.PubMed/NCBI
51	Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, et al: Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 45:1479–1482. 2013. View Article : Google Scholar : PubMed/NCBI
52	Yoshida KI, Nakano Y, Honda-Kitahara M, Wakai S, Motoi T, Ogura K, Sano N, Shibata T, Okuma T, Iwata S, et al: Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. Mod Pathol. 32:1751–1761. 2019. View Article : Google Scholar : PubMed/NCBI
53	Imai R, Kamada T and Araki N; Working Group for Bone, . Soft Tissue Sarcomas: Carbon ion radiation therapy for unresectable sacral chordoma: An analysis of 188 cases. Int J Radiat Oncol Biol Phys. 95:322–327. 2016. View Article : Google Scholar : PubMed/NCBI